The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The 340B Drug Pricing Program was developed more than three decades ago to help improve access to medicines for vulnerable patients 4 via manufacturer discounts to specific nonprofit hospitals and ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The high list prices of gene therapies command the media’s attention and that of policymakers and payers. Late last year, the Food and Drug Administration (FDA) approved the world’s first gene therapy ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

Too often Kansans hear the rotors of another air ambulance carrying a patient from a rural area to an urban health care facility to receive treatment. Like a beating drum, the sound reminds us of the ...